• H. Yasemin Balaban, Abdullah Tarık Aslan, Şefika Nur Ayar, Osman Dağ, Alpaslan Alp, Cem Şimşek, Cavanşir Vahabov, Tolga Yıldırım, Hakan Göker, Yahya Büyükaşık, and Halis Şimşek.
• Department of Gastroenterology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
• Turk J Med Sci. 2021 Jun 28; 51 (3): 1229-1233.

Background/AimHepatitis B virus (HBV) vaccination rates are insufficient in high-risk patients worldwide. This study aimed to investigate the screening, immunization, and vaccination rates in three high-risk groups for HBV infection: allogeneic hematopoietic stem cell transplantation (AHSCT), renal transplantation (RT), and chronic hepatitis C (CHC) groups.Materials And MethodsThe serological data of consecutive patients between 2014 and 2019 were reviewed using the hospital database.ResultsThe HBV screening rates were 100.0%, 90.4%, and 82.4% in the AHSCT, CHC, and RT groups, respectively (p = 0.003). The immunization rates against HBV through either previous exposure or vaccination were 79.5%, 71.7%, and 46.5% in the AHSCT, RT, and CHC groups, respectively (p < 0.001). The HBV vaccination rate was significantly low in the CHC group (71.5%, 69.0%, 34.6% in the AHSCT, RT, and CHC groups, respectively, p < 0.001). If patients lost their immunity due to immunosuppressive therapy were accounted, the vaccination rates increased to 95.2% in the AHSCT group and 72.9% in the RT group. The rate of annual screening for HBV status was 97.9% in the AHSCT group, but it was only 23.9% in the RT group.ConclusionHBV screening and vaccination rates were significantly lower in the RT and CHC groups than in the AHSCT group.This work is licensed under a Creative Commons Attribution 4.0 International License.

13 keywords...

hide…